scFv(TACSTD2)-CD3zeta CAR-T Lentivirus

The scFv(TACSTD2)-CD3zeta CAR-T Lentivirus is a high-titer, replication-incompetent viral vector designed for the stable expression of a TROP2-specific Chimeric Antigen Receptor (CAR) in primary human T cells. The genetic payload encodes a specialized fusion protein comprising a high-affinity single-chain variable fragment (scFv) derived from an anti-TACSTD2 antibody, linked via a transmembrane hinge to the CD3-zeta (CD3ζ) intracellular signaling domain. TACSTD2, also known as Tumor-Associated Calcium Signal Transducer 2 or TROP2, is a cell-surface glycoprotein that is significantly upregulated in numerous epithelial malignancies. By utilizing a lentiviral delivery system, this product ensures efficient integration of the CAR construct into the host cell genome, allowing for the generation of effector T cells that can recognize and bind to TROP2-expressing cells in an MHC-independent manner. This binding event triggers the CD3ζ signaling cascade, leading to T-cell activation, proliferation, and the subsequent release of cytotoxic granules to induce apoptosis in target tumor cells.

This lentiviral product is an essential tool for researchers focused on the development of adoptive cell therapies for solid tumors. Given the broad expression of TROP2 in cancers such as triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma, the scFv(TACSTD2)-CD3zeta CAR-T system is primarily used in preclinical efficacy studies to evaluate the potency of redirected T cells. It is widely employed in in vitro cytotoxicity assays to measure specific lysis of cancer cell lines and in cytokine profiling experiments to monitor the secretion of IFN-gamma and IL-2 upon antigen engagement. Additionally, the lentivirus is instrumental in establishing humanized or cell-line-derived xenograft (CDX) mouse models to study T-cell infiltration, persistence, and the metabolic challenges within the tumor microenvironment. Beyond basic oncology research, it serves as a reliable benchmark for testing novel modifications in CAR architecture, such as the addition of various co-stimulatory domains or the implementation of “armored” CAR strategies to enhance therapeutic durability.